We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Probe May Detect Early Cancer

By Biotechdaily staff writers
Posted on 24 Aug 2005
Scientists have discovered a new way to spot subtle chemical changes in the growth of tumors, which may aid the early detection of cancer and other diseases. More...
Their findings were reported in the August 14, 2005, issue of Nature Chemical Biology.

A molecule that can label proteases--protein-chewing enzymes that blast into overdrive in cancerous cells--has been created by Matthew Bogyo, Ph.D., assistant professor of pathology, and colleagues at Stanford University School of Medicine (Palo Alto, CA, USA). The new molecule contains a fluorescent tag that flashes brightly enough to be seen with conventional imaging equipment.

This new activity-based probe is unusual in that it only lights up when the proteases are active. Since it works in living cells, the probe could potentially be used for whole-body imaging for the detection of early warning signs of cancer. Proteases work overtime in tumors that are getting ready to spread, or metastasize, and in angiogenesis. Other cells with hyperactive proteases include cells affected by arthritis, osteoporosis, atherosclerosis, and neurodegenerative disorders such as Alzheimer's.

"This is an important tool for understanding the biochemistry of proteases, and how they play a role in diseases like cancer,” said Dr. Bogyo. "And it's noninvasive and fairly nontoxic, in that it doesn't involve radioisotopes.”

The probe has a number of advantages over other enzyme imaging probes. In one innovation, the scientists added a chemical subunit called a quencher that keeps the probe dark until the protease is activated. The chemical changes activating the enzyme switch the probe on "like a molecular beacon,” noted Dr. Boygo. Since the probe is small enough to pass easily across cell membranes, it can be used inside living cells. The probe also forms a permanent bond with its targeted protease, allowing it to track where the protease is active.

In addition to making new probes, Dr. Bogyo and his team are working on imaging applications. "We have made the tool, now we want to go and use it,” observed Galia Blum, a postdoctoral scholar in Dr. Bogyo's lab and the study's lead author. "Our next step is to generate whole-body images in mice.”





Related Links:
Stanford Medical School

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.